Access to Transplant Archives - Page 4 of 6

Dialysis Patient Advocates Applaud Ruling in Case Against CMS

Hannah Bracamonte2024-03-29T01:13:40+00:00January 25th, 2017|Categories: Access to Transplant, Charitable Premium Assistance, Legal Defense, Medigap Coverage, Press Release|

Federal court blocks CMS regulation that would give insurers veto power over access to private coverage; judge calls it ‘arbitrary and capricious’ Washington, D.C. – Advocates for dialysis patients are celebrating a federal court ruling today to grant a preliminary injunction preventing the U.S. Department of Health and Human Services (HHS) from implementing a regulation that could force patients off their current health insurance and jeopardize their access to care. In enjoining the regulation’s enforcement, the U.S. District Court for the Eastern District of Texas held that the rule was 1) procedurally defective because HHS adopted it without first giving [...]

Dialysis Patient Advocates Seek Restraining Order Against CMS

Hannah Bracamonte2024-03-29T01:13:41+00:00January 9th, 2017|Categories: Access to Transplant, Care Coordination, Charitable Premium Assistance, Medigap Coverage, Press Release, State Advocacy|

Lawsuit charges that CMS rule to take effect Jan. 13 gives insurers illegal veto power over access to private coverage Washington, D.C. – Advocates for dialysis patients filed suit in federal court today to prevent the U.S. Department of Health and Human Services (HHS) from enforcing a rule that could force patients off their current health plans and jeopardize their access to care. The regulation, which the Centers for Medicare and Medicaid Services (CMS) issued Dec. 13 outside the formal rulemaking process, gives insurers the power to prevent dialysis patients from receiving charitable premium assistance that makes it possible for [...]

Protecting Dialysis Patients’ Health Coverage

Hannah Bracamonte2024-03-29T01:13:41+00:00January 9th, 2017|Categories: Access to Transplant, Blog, Care Coordination, Charitable Premium Assistance, Legal Defense, Medigap Coverage|Tags: Health Insurance Exchange|

By Hrant Jamgochian, CEO Dialysis Patient Citizens Across the country, thousands of patients with end-stage renal disease (ESRD) face the agonizing choice of paying for necessities such as rent and food, or paying the insurance premiums that enable them to get dialysis and other critical care. Fortunately, ESRD patients have options. Thanks to federal law, they can enroll in Medicare at any age. Or, if they would rather keep a private insurance plan, they can apply for financial help from charities such as the American Kidney Fund. These payments are a lifeline that enables patients to maintain their existing coverage and [...]

Dialysis Patients Outraged by CMS Move Giving Insurers Illegal Veto Power Over Access to Private Coverage

Hannah Bracamonte2024-03-29T01:13:41+00:00December 19th, 2016|Categories: Access to Transplant, Care Coordination, Charitable Premium Assistance, Legal Defense, Medigap Coverage, Press Release|

Dialysis Patient Citizens says CMS rule tacitly allows insurers to discriminate based on patients’ health condition Washington, D.C. – Advocates for dialysis patients are outraged by an interim final rule issued late yesterday by the Centers for Medicare and Medicaid Services (CMS) that could force patients off their current health plans and jeopardize their access to care. The rule, which CMS wrote with the stated purpose of ensuring that dialysis patients receive accurate information about their health coverage options, instead empowers insurers to prevent those patients from receiving charitable premium assistance that makes their health insurance affordable. “The administration is [...]

2015 Year in Review

Hannah Bracamonte2024-03-29T01:50:30+00:00January 19th, 2016|Categories: 5-Star Ratings, Access to Transplant, Article, Care Coordination, Charitable Premium Assistance, Dialysis Funding, Innovation, Medicare Advantage|Tags: Annual Accomplishments|

Happy New Year! In 2015, DPC leadership and its strong patient advocacy efforts at the state level fought to: prevent dramatic cuts to dialysis funding in Alabama and Illinois and preserve charity payments for dialysis patient premiums. Other highlights include: The opportunity for DPC CEO Hrant Jamgochian and board member Bob Lee to testify in front of the Oregon insurance commissioner on the discriminatory language found in two private insurance plans that would limit coverage for ESRD patients. The commissioner ruled against the language. DPC board member Danny Iniguez discussed health disparities in kidney disease at the National Black Caucus [...]

DPC Urges CMS to Prioritize Patient Access

Hannah Bracamonte2024-03-29T01:50:30+00:00January 19th, 2016|Categories: Access to Transplant, Care Coordination, Charitable Premium Assistance, Medicare Advantage, Medigap Coverage, Transportation Services|Tags: Health Insurance Exchange|

Last month, DPC sent a letter commenting on the “Notice of Benefit and Payment Parameters for 2017” proposed rule. This annual rule by the Centers for Medicare and Medicaid Services (CMS) contains proposed changes to the exchange plan coverage of the Affordable Care Act. DPC’s letter focuses on the importance of insurance coverage and network quality for end-stage renal disease (ESRD) patients. One issue the letter comments on pertains to network adequacy. Network adequacy describes an insurance plan’s ability to provide a sufficient amount of in-network providers to subscribers in the plan. Suggestions to improve network adequacy include requiring all [...]

JAMA Study Examines Obstacles Preventing Kidney Transplants

Hannah Bracamonte2024-03-29T01:50:32+00:00August 14th, 2015|Categories: Access to Transplant, Article|

It is well known that the best treatment for end-stage renal disease patients is a kidney transplant. While there are many health factors that affect a patients’ ability to receive a transplant, a recent study found that only 28 percent of adult patients beginning dialysis were even referred for kidney transplant evaluations. The study, published in the Journal of American Medical Association, examined 15,000 patients within Georgia’s three transplant centers. Referral rates varied from 0% to 75% in some dialysis facilities. Researchers found that facilities with the lowest referral rate were “likely to be nonprofit, hospital-based, have more patients, treat patients [...]

DPC Board Members to Serve on Three Technical Expert Panels

Hannah Bracamonte2024-03-29T01:50:33+00:00April 7th, 2015|Categories: 5-Star Ratings, Access to Transplant, Treatment Options|

The Centers for Medicare and Medicaid Services (CMS) regularly schedules technical expert panels (TEPs) to advise the agency on quality measures. In the words of CMS, a TEP is “a group of stakeholders and experts who provide technical input…on the development, selection, and maintenance of measures for which CMS contractors are responsible.” CMS is contracting with the University of Michigan Kidney Epidemiology and Cost Center (UM-KECC) to host a TEP on the Dialysis Facility Compare star rating system. While the complete roster of participants is not public yet, we are pleased to announce that DPC Interim President Jack Reynolds was selected [...]

DPC Urges Medicare Agency to Withdraw Proposal That Could Weaken Protections for Transplant Patients

Hannah Bracamonte2024-03-29T02:08:06+00:00March 6th, 2014|Categories: Access to Transplant, Article, Comment Letter, Immunosuppressive Drug Coverage, Improve Access to Care|

Dialysis Patient Citizens (DPC) weighed in against a Medicare proposal that would complicate some transplant patients’ access to immunosuppressive drugs. Medicare Part D, like other private health plans, uses drug formularies to keep down costs. Formularies favor certain drugs over others in exchange for discounts. Patients are encouraged to ask their doctors to first prescribe medications on the formulary to take advantage of lower co-pays. Often a patient’s condition can be addressed by a drug on the formulary, but many transplant patients find that “first-line” immunosuppressive treatments aren’t effective or have serious side-effects. For this reason, DPC told CMS: “Immunosuppressive [...]